Literature DB >> 18831527

Downregulation of glial glutamate transporters after dopamine denervation in the striatum of 6-hydroxydopamine-lesioned rats.

E K Y Chung1, L W Chen, Y S Chan, K K L Yung.   

Abstract

Overactivity of glutamatergic neurotransmission in the basal ganglia is known to be closely related to the onset and pathogenesis of Parkinson's disease. Glutamate homeostasis around glutamatergic synapses is tightly regulated by two groups of glutamate transporters: glial glutamate transporters GLT1 (EAAT2) and GLAST (EAAT1), and neuronal glutamate transporter EAAC1. In order to investigate the changes of glutamate transporters after the onset of Parkinson's disease, unilateral 6-hydroxydopamine-lesioned rat, an animal model of Parkinson's disease, was employed. By immunofluorescence and Western blot analyses, GLT1 and GLAST proteins were significantly reduced in the striatum with lesion. No change in GLT1 and GLAST protein was found in the substantia nigra. The reduction of GLT1 protein in the striatum was more prominent than that of GLAST protein (approximately 40% vs. 20%). In addition, EAAC1 protein was found to be increased in the substantia nigra pars reticulata of the lesioned rats but not in the striatum. The present results indicate that reductions of GLT1 and GLAST may impair glutamate homeostasis around glutamatergic synapses in the striatum and contribute to over-spills of glutamate in the system. An increase in the EAAC1 level in the substantia nigra pars reticulata may increase GABA synthesis and enhance GABAergic neurotransmission. These results indicate that there are differential and distinct modulations of glutamate transporters after dopamine denervation in the 6-hydroxydopamine-lesioned rat. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18831527     DOI: 10.1002/cne.21852

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  41 in total

1.  Synaptic and nonsynaptic localization of protocadherin-gammaC5 in the rat brain.

Authors:  Yanfang Li; David R Serwanski; Celia P Miralles; Christopher G Fiondella; Joseph J Loturco; Maria E Rubio; Angel L De Blas
Journal:  J Comp Neurol       Date:  2010-09-01       Impact factor: 3.215

2.  Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model.

Authors:  Tanya Chotibut; Samantha Meadows; Ella A Kasanga; Tamara McInnis; Mark A Cantu; Christopher Bishop; Michael F Salvatore
Journal:  Mov Disord       Date:  2017-06-20       Impact factor: 10.338

Review 3.  Glutamate transporter EAAT2: regulation, function, and potential as a therapeutic target for neurological and psychiatric disease.

Authors:  Kou Takahashi; Joshua B Foster; Chien-Liang Glenn Lin
Journal:  Cell Mol Life Sci       Date:  2015-06-02       Impact factor: 9.261

Review 4.  Role of transcription factor yin yang 1 in manganese-induced reduction of astrocytic glutamate transporters: Putative mechanism for manganese-induced neurotoxicity.

Authors:  Pratap Karki; Keisha Smith; James Johnson; Michael Aschner; Eunsook Lee
Journal:  Neurochem Int       Date:  2014-08-13       Impact factor: 3.921

5.  Acetyl-L-Carnitine via Upegulating Dopamine D1 Receptor and Attenuating Microglial Activation Prevents Neuronal Loss and Improves Memory Functions in Parkinsonian Rats.

Authors:  Sonu Singh; Akanksha Mishra; Neha Srivastava; Rakesh Shukla; Shubha Shukla
Journal:  Mol Neurobiol       Date:  2016-12-14       Impact factor: 5.590

Review 6.  An emerging role of astrocytes in vascular contributions to cognitive impairment and dementia.

Authors:  Brittani R Price; Christopher M Norris; Pradoldej Sompol; Donna M Wilcock
Journal:  J Neurochem       Date:  2018-01-22       Impact factor: 5.372

Review 7.  The role of astrocytic glutamate transporters GLT-1 and GLAST in neurological disorders: Potential targets for neurotherapeutics.

Authors:  Edward Pajarillo; Asha Rizor; Jayden Lee; Michael Aschner; Eunsook Lee
Journal:  Neuropharmacology       Date:  2019-03-06       Impact factor: 5.250

8.  Astrocytic dynamin-like protein 1 regulates neuronal protection against excitotoxicity in Parkinson disease.

Authors:  Jake G Hoekstra; Travis J Cook; Tessandra Stewart; Hayley Mattison; Max T Dreisbach; Zachary S Hoffer; Jing Zhang
Journal:  Am J Pathol       Date:  2014-12-04       Impact factor: 4.307

9.  Heterogeneity of astrocyte and NG2 cell insertion at the node of ranvier.

Authors:  David R Serwanski; Peter Jukkola; Akiko Nishiyama
Journal:  J Comp Neurol       Date:  2016-08-18       Impact factor: 3.215

10.  Ceftriaxone increases glutamate uptake and reduces striatal tyrosine hydroxylase loss in 6-OHDA Parkinson's model.

Authors:  Tanya Chotibut; Richard W Davis; Jennifer C Arnold; Zachary Frenchek; Shawn Gurwara; Vimala Bondada; James W Geddes; Michael F Salvatore
Journal:  Mol Neurobiol       Date:  2013-12-03       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.